Lyell Immunopharma, Inc.
LYEL
$10.76
-$0.21-1.91%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -42.68M | -52.20M | -191.94M | -44.58M | -45.81M |
| Total Depreciation and Amortization | 3.14M | 3.44M | 5.03M | 4.68M | 4.90M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 5.97M | 3.57M | 139.63M | 3.82M | 3.77M |
| Change in Net Operating Assets | -876.00K | -9.55M | 34.00K | 1.04M | -954.00K |
| Cash from Operations | -34.46M | -54.74M | -47.24M | -35.04M | -38.09M |
| Capital Expenditure | -168.00K | -246.00K | -44.00K | -59.00K | -331.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -31.35M | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 12.82M | 69.71M | 84.90M | 1.98M | 45.34M |
| Cash from Investing | 12.65M | 69.47M | 53.51M | 1.92M | 45.01M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 184.00K | -- | 437.00K | 0.00 | 862.00K |
| Repurchase of Common Stock | -- | -- | 0.00 | 0.00 | 0.00 |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -1.00K | 1.00K | -- | -- | -- |
| Cash from Financing | 183.00K | 1.00K | 437.00K | 0.00 | 862.00K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -21.63M | 14.73M | 6.70M | -33.12M | 7.78M |